AMG 531
Phase 2/3Completed 3 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Conditions
Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Trial Timeline
Nov 1, 2006 → Sep 1, 2011
NCT ID
NCT00440037About AMG 531
AMG 531 is a phase 2/3 stage product being developed by Kyowa Kirin for Immune (Idiopathic) Thrombocytopenic Purpura (ITP). The current trial status is completed. This product is registered under clinical trial identifier NCT00440037. Target conditions include Immune (Idiopathic) Thrombocytopenic Purpura (ITP).
What happened to similar drugs?
7 of 20 similar drugs in Immune (Idiopathic) Thrombocytopenic Purpura (ITP) were approved
Approved (7) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00440037 | Phase 2/3 | Completed |
Competing Products
20 competing products in Immune (Idiopathic) Thrombocytopenic Purpura (ITP)